Genscript Biotech Corp
HKEX:1548
Intrinsic Value
Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. [ Read More ]
The intrinsic value of one
Genscript Biotech Corp
stock under the Base Case scenario is
35.52
HKD.
Compared to the current market price of 12.42 HKD,
Genscript Biotech Corp
is
Undervalued by 65%.
Genscript Biotech Corp's market capitalization is 26.3B HKD.
Genscript Biotech Corp stock price is 12.42 HKD.
Genscript Biotech Corp stock price (12.42 HKD) is 65% less than its Intrinsic Value (35.52 HKD).
Genscript Biotech Corp stock (11.69 HKD) is 6% less than its price (12.42 HKD). Open DCF Valuation
Genscript Biotech Corp stock price (12.42 HKD) is 79% less than its Relative Value (59.34 HKD). Open Relative Valuation
Genscript Biotech Corp has upside potential of 141% compared to the average analyst price target.
Open Wall St Estimates
Genscript Biotech Corp's ROIC (Return on Invested Capital) has increased in the last 3 years from -38% to -32%, and is approaching profitability.
Genscript Biotech Corp's Revenue has grown by an exceptional 34% over the past 12 months.
Genscript Biotech Corp's long-term assets (3B USD) exceed its long-term liabilties (2B USD).
Genscript Biotech Corp's ROE (Return on Equity) for the past 12 months is negative and is equal to -8%.
Genscript Biotech Corp's ROE (Return on Equity) has significantly increased in the last 3 years from -32% to -8%, and is approaching profitability.
Genscript Biotech Corp's Revenue has been growing by an exceptional 29% per year for the last 3 years.
Genscript Biotech Corp has negative Operating Income for the last twelve months.
Genscript Biotech Corp has negative Net Income for the last twelve months.
Genscript Biotech Corp's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -32%.
Genscript Biotech Corp's Revenue is forecast to grow at a rate of 50% per year over the next 3 years.
Genscript Biotech Corp has positive Gross Profit for the last twelve months.
Genscript Biotech Corp's D/E (Debt to Equity) is very low and is equal to 0.29.
Genscript Biotech Corp has negative Free Cash Flow for the last twelve months.
Genscript Biotech Corp has negative three-year average ROE (Return on Equity): -26%. The company is not efficient at transforming stockholders' equity into net income.
Genscript Biotech Corp has negative three-year average ROIC (Return on Invested Capital): -52%. The company is not efficient at using invested capital to generate operating income.
Genscript Biotech Corp's short-term assets (2B USD) exceed its short-term liabilties (495m USD).
Genscript Biotech Corp has negative Net Debt. This means that the company has more cash and short-term investments (2B USD) than debt (408m USD).
Genscript Biotech Corp's Altman Z-Score is very high and is equal to 12.31.
Genscript Biotech Corp doesn't generate enough operating income (-387m USD) to safely cover interest payments on its debt (3m USD).
Valuation Backtest
Genscript Biotech Corp
Run backtest to discover the historical profit from buying and selling
Genscript Biotech Corp
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Genscript Biotech Corp
Balance Sheet Decomposition
Genscript Biotech Corp
| Current Assets | 2.4B |
| Cash & Short-Term Investments | 1.9B |
| Receivables | 300m |
| Other Current Assets | 125.1m |
| Non-Current Assets | 1B |
| Long-Term Investments | 90.8m |
| PP&E | 750.9m |
| Intangibles | 20m |
| Other Non-Current Assets | 172.4m |
| Current Liabilities | 494.8m |
| Accounts Payable | 40m |
| Accrued Liabilities | 165.9m |
| Short-Term Debt | 56.9m |
| Other Current Liabilities | 232m |
| Non-Current Liabilities | 1.5B |
| Long-Term Debt | 351.1m |
| Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
Genscript Biotech Corp
|
Revenue
|
839.5m
USD
|
|
Cost of Revenue
|
-430m
USD
|
|
Gross Profit
|
409.6m
USD
|
|
Operating Expenses
|
-797m
USD
|
|
Operating Income
|
-387.4m
USD
|
|
Other Expenses
|
291.9m
USD
|
|
Net Income
|
-95.5m
USD
|
Free Cash Flow Analysis
Genscript Biotech Corp
Profitability Score
Profitability Due Diligence
Genscript Biotech Corp's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Genscript Biotech Corp's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Genscript Biotech Corp's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Genscript Biotech Corp's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Genscript Biotech Corp
According to Wall Street analysts, the average 1-year price target for
Genscript Biotech Corp
is 29.87 HKD
with a low forecast of 23.23 HKD and a high forecast of 34.65 HKD.
Shareholder Return
Price
Genscript Biotech Corp
| Average Annual Return | 31.3% |
| Standard Deviation of Annual Returns | 102.27% |
| Max Drawdown | -75% |
| Market Capitalization | 26.3B HKD |
| Shares Outstanding | 2 113 863 177 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Genscript Biotech Corp
Country
Industry
Market Cap
Dividend Yield
Description
Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2015-12-30. The firm operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
Contact
IPO
Employees
Officers
The intrinsic value of one
Genscript Biotech Corp
stock under the Base Case scenario is
35.52
HKD.
Compared to the current market price of 12.42 HKD,
Genscript Biotech Corp
is
Undervalued by 65%.
You don't have any saved screeners yet
